Qurient Co., Ltd.

Lead Discovery Center Gmbh

Institut Pasteur Korea

Qli5 Therapeutics Ag

Kiyean Nam

Jaeseung Kim

Dongsik Park

Yeejin Jeon

SaeYeon Lee

Mooyoung Seo

Jeongjun Kim

Sangchul Lee

Gunther Zischinsky

Jan Eickhoff

Sunhee Kang

Gahee Choi

Sung-Jun Han

Seohyun Ahn

Doohyung Lee

Jiye Ahn

Young-In Yang

Young Sam Park

Jinhwa Lee

Hana Kim

Uwe Koch

Jung Yoon Kim

Peter Nussbaumer

Carsten Schultz-Fademrecht

Axel Choidas

Bert Klebl

Donghoon Yu

Zaesung No

Min Jung Seo

Hwan Kyu Kang

Juhee Kang

Sumi Lee

Anke Unger

Chunwon Jung

Minjung Seo

Jeongjea Seo

Yunmi Lee

Chun-won Jung

Jung Hwan Kim

Yeong-in Yang

Seung-Joo Lee

Wongyun Ahn

Ryang Yeo Kim

Yeong-In Yang

Chun-Won Jung

Robert Huber

Julian Engel

Kevin Pethe

Soohyun Oh

Carsten Degenhart

The present invention relates to different forms of the compound 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide and to methods of making such forms/compounds. The present invention furthermore relates to mono-acid addition salts thereof, to methods of making such mono-acid addition salts and to pharmaceutical compositions comprising any of the aforementioned compounds. Furthermore, the present invention relates to uses of any of these compounds.

Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide

The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.

Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase

The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; Xand Xare independently, at each occurrence, CRor N; Y is C-Calkylene, wherein alkylene is optionally substituted with one to two C-Calkyl groups; Ris selected from the group consisting of hydrogen, halogen, C-Calkoxy, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R, n being 0 or 1; Ris selected from the group consisting of hydrogen, halogen, C-Calkyl, &#x2014;NH, &#x2014;NHR, &#x2014;NRRand &#x2014;NH&#x2014;(R)&#x2014;R; Ris selected from the group consisting of hydrogen, hydroxyl, OR, &#x2014;NRR, C-Calkoxy, C-Calkyl, C-Ccycloalkyl, C-Chaloalkyl, &#x2014;C(O)NHR, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Rgroups; and Ris selected from the group consisting of &#x2014;NH, &#x2014;N(R)(V)R, &#x2014;NH(V)&#x2014;OR, &#x2014;NHC(O)R, and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease. 

2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors

The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

Quinoline derivatives as TAM RTK inhibitors

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR, C&#x2550;O, C&#x2550;S, OP(O)(O), P&#x2550;O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C&#x2550;O, O, S, CH, or NR; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis. 

Anti-inflammation compounds

Growing community of inventors

Gyeonggi-do, South Korea

Kiyean Nam